AU7692696A - Heteroaryl derivatives - Google Patents

Heteroaryl derivatives

Info

Publication number
AU7692696A
AU7692696A AU76926/96A AU7692696A AU7692696A AU 7692696 A AU7692696 A AU 7692696A AU 76926/96 A AU76926/96 A AU 76926/96A AU 7692696 A AU7692696 A AU 7692696A AU 7692696 A AU7692696 A AU 7692696A
Authority
AU
Australia
Prior art keywords
heteroaryl derivatives
heteroaryl
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76926/96A
Inventor
Leoluca Criscione
Pascal Rigollier
Heinrich Rueger
Walter Schilling
Tibur Schmidlin
Stefan Stutz
Marina Tintelnot-Blomley
Yasuchika Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US56602495A priority Critical
Priority to US566024 priority
Application filed by Ciba Geigy AG, Novartis AG filed Critical Ciba Geigy AG
Priority to PCT/EP1996/005056 priority patent/WO1997020821A1/en
Publication of AU7692696A publication Critical patent/AU7692696A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
AU76926/96A 1995-12-01 1996-11-18 Heteroaryl derivatives Abandoned AU7692696A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US56602495A true 1995-12-01 1995-12-01
US566024 1995-12-01
PCT/EP1996/005056 WO1997020821A1 (en) 1995-12-01 1996-11-18 Heteroaryl derivatives

Publications (1)

Publication Number Publication Date
AU7692696A true AU7692696A (en) 1997-06-27

Family

ID=24261137

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76926/96A Abandoned AU7692696A (en) 1995-12-01 1996-11-18 Heteroaryl derivatives

Country Status (3)

Country Link
AU (1) AU7692696A (en)
WO (1) WO1997020821A1 (en)
ZA (1) ZA9610021B (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
AU6309698A (en) * 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
WO1999027965A1 (en) * 1997-11-28 1999-06-10 Banyu Pharmaceutical Co., Ltd. Antihyperlipemic agents
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
DE19824175A1 (en) * 1998-05-29 1999-12-02 Novartis Ag Amino-azole compounds
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
AR019626A1 (en) * 1998-06-08 2002-02-27 Schering Corp Neuropeptide Y5 receptor antagonists.
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
AU3840000A (en) 1999-04-20 2000-11-02 Meiji Seika Kaisha Ltd. Tricyclic compounds
IL139454D0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
ES2342344T3 (en) 1999-11-26 2010-07-05 SHIONOGI & CO., LTD. NPY-Y5 antagonists.
AT303383T (en) * 1999-12-17 2005-09-15 Chiron Corp Bicyclic inhibitors of glycogen synthase kinase 3
EP1607396A1 (en) * 1999-12-17 2005-12-21 Chiron Corporation Bicyclic inhibitors of glycogen synthase kinase 3
KR100711817B1 (en) * 1999-12-17 2007-05-02 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Bicyclic inhibitors of glycogen synthase kinase 3
EP1306372B1 (en) * 2000-03-31 2009-11-18 Nippon Shinyaku Co., Ltd. Heterocycle derivatives and drugs
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
US6730792B2 (en) 2000-07-13 2004-05-04 Eli Lilly And Company β3 adrenergic agonists
PE00082003A1 (en) 2001-06-19 2003-01-22 Squibb Bristol Myers Co dual inhibitors of PDE 4 and PDE 7
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
CA2403307A1 (en) 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
MXPA04010539A (en) 2002-04-26 2005-01-25 Nippon Shinyaku Co Ltd Quinazoline derivative and medicine.
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JP2006501243A (en) * 2002-08-23 2006-01-12 カイロン コーポレイション Inhibitors of pyrrole-based glycogen synthase kinase 3
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP4806628B2 (en) 2003-05-05 2011-11-02 プロビオドルグ エージー Glutaminyl cyclase inhibitor
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
CN1902177A (en) 2003-09-22 2007-01-24 万有制药株式会社 Novel piperidine derivative
WO2005040157A2 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
CA2544573A1 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
KR101123549B1 (en) 2004-11-01 2012-04-18 아밀린 파마슈티칼스, 인크. Treatment of obesity and related disorders
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
JP5154927B2 (en) 2005-05-30 2013-02-27 Msd株式会社 Novel piperidine derivatives
JPWO2007018248A1 (en) 2005-08-10 2009-02-19 萬有製薬株式会社 Pyridone compound
CA2619770A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP1940374A2 (en) 2005-10-21 2008-07-09 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
EP1953165B1 (en) 2005-11-10 2012-02-01 Msd K.K. Aza-substituted spiro derivative
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (en) 2006-11-30 2014-06-18 プロビオドルグ エージー Novel inhibitors of glutaminyl cyclase
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
DK2170930T3 (en) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonists of guanylate cyclase, useful for the treatment of gastrointestinal disorders, inflammation, cancer and other diseases
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
ES2627848T3 (en) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (en) 2008-06-19 2011-12-01 Msd株式会社 Spirodiamine-diarylketoxime derivatives
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8592457B2 (en) 2008-10-30 2013-11-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CA2789440A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP5812500B2 (en) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション Novel β3 adrenergic receptor agonist
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012220595B2 (en) 2011-02-25 2015-07-16 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme Receptor antagonists 2-4-pyridyloxy-nitrile orexin
KR20150036245A (en) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 Antidiabetic tricyclic compounds
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016522216A (en) 2013-06-05 2016-07-28 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
JP2017529389A (en) 2014-08-29 2017-10-05 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956495A (en) * 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
FR2389613B2 (en) * 1977-05-05 1980-12-05 Synthelabo
AT384218B (en) * 1985-12-04 1987-10-12 Gerot Pharmazeutika Processes for production of new quinazoline derivatives

Also Published As

Publication number Publication date
WO1997020821A1 (en) 1997-06-12
ZA9610021B (en) 1997-06-01

Similar Documents

Publication Publication Date Title
AU742928C (en) N-alkanoylphenylalanine derivatives
AU699163B2 (en) Quinazoline derivatives
AU693013B2 (en) Novel tetracycline derivatives
IL152383D0 (en) 5-amino-3-cyano-4-ethylsulfinyl-1- phenyl-pyrazole derivatives
AU4770496A (en) Novel compounds
SG50747A1 (en) Comptothecin derivatives
ZA9610023B (en) Heteroaryl compounds
AU4844396A (en) Imidazoquinazoline derivatives
AU5577196A (en) Isothiazolones
AU5776996A (en) Substituted benzylaminopiperidine compounds
AU5647094A (en) Pyrrolo-pyridine derivatives
AU1151099A (en) Azaoxindole derivatives
IL135376D0 (en) Hydroxyalkyl-phenyl derivatives
AU1209597A (en) Benzimidazole derivatives
AU1554897A (en) 6-phenylpyridyl-2-amine derivatives
AU5343196A (en) Quinazoline derivative
AU6785996A (en) 2-alkylpyrrolidines
AU5235796A (en) o-hydroxyphenyl-s-triazines
AU6378696A (en) Novel pre-dyes
AU7159994A (en) 3-aryl-4-hydroxy-delta3-dihydrofuranone derivatives
AU4875396A (en) Benzoyl derivatives
AU5343496A (en) Quinazoline derivative
AU5703196A (en) Piperazine derivatives
AU1441097A (en) Heterocycle-condensed morphinoid derivatives (ii)
AU7935398A (en) Diaminorhodamine derivatives